clinical-trials-2017-scientifictracks-abstracts

46 / 46

Page 89
Notes:
conferenceseries.com
Volume 7, Issue 5 (Suppl) J Clin Trials, an open access journal
ISSN:2167-0870 Clinical Trials 2017
September 11-13, 2017
September 11-13, 2017 San Antonio, USA
4th International Conference on
Cl inical Tr ial s
Precision and accuracy of the new Xprecia stride mobile coagulometer
Francesco Piacenza
National Institute of Health and Aging, Italy
Oral anticoagulation therapy (OAT) with coumarins (vitamin K antagonist) is the most used against thromboembolism.
Prothrombin time International Normalized Ratio (PT-INR) monitoring is fundamental to determine coumarins dosage
and prevent bleeding complications or thrombotic events. In this contest, the method used for providing the INRmeasurements
is crucial. Several studies measured both PT-INR precision and accuracy of the most known mobile coagulometer. However,
no data on the new XPrecia Stride Mobile Coagulometer (Siemens) are available in literature. The aim of this work is to analyze
precision and accuracy of the new XPrecia Stride mobile coagulometer to provide recommendations for clinical use and
quality control. A total of 163 patients (mean age=77.4 years old) under Warfarin OAT for whom the INR was assessed by both
the traditional cs 2100i Sysmex and the new Xprecia Stride Mobile Coagulometer were included in this study. The precision of
the new mobile coagulometer resulted very well (CV<3%). The analytical accuracy was also in line with other known devices
(MRD=6.78%). Finally, the clinical accuracy was acceptable (deviation>15% from the true value in 20% of cases). Considering
the overall results obtained by the new Xprecia Stride in comparison to that one’s obtained from the other commercial devices,
we can conclude that the new coagulometer is enough reliable for clinical settings. However, a larger trial to confirm these data
is needed.
Biography
Francesco Piacenza has completed his PhD from the Polytechnic University of Marche. He continued the research activity on age related diseases by leading
the Post-doctoral studies at the National Institute of Health and Aging. In 2011, he also acquired the title of Clinical and Epidemiological Research Coordinator at
the same institute. He is actually a Specialist in Clinical Biochemistry at the National Institute of Health and Aging in Ancona, Italy. He has published more than 40
papers in peer-reviewed journals with impact factor and is an Editorial Board Member of various journals.
Francesco Piacenza, J Clin Trials 2017, 7:5 (Suppl)
DOI: 10.4172/2167-0870-C1-019